XML 90 R71.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Collaborative Agreements |  |  |
License fee expense | $ 0.7 | $ 1.6 | $ 0.9
Medarex |  |  |
Collaborative Agreements |  |  |
Period from the first commercial sale of licensed product for royalty payment | 10 years |  |
Rockefeller |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | $ 3.8 |  |
Southampton |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | 1.0 |  |
Amgen |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | 0.9 |  |
Seattle Genetics | Glembatumumab Vedotin |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | 5.0 |  |
Seattle Genetics | CDX-014 |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | 8.5 |  |
Yale |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | 3.0 |  |
MedImmune | Obtaining specified regulatory and development |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | 45.0 |  |
MedImmune | Specified annual net sales thresholds are met |  |  |
Collaborative Agreements |  |  |
Potential milestone payment | $ 125.0 |  |

X
- Definition Represents the period from the first commercial sale of licensed product for royalty payment under the collaborative arrangement. + References No definition available. + Details
Name: | cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct
Namespace Prefix: | cldx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_MedarexIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_RockefellerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_UniversityOfSouthamptonUKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_SeattleGeneticIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=cldx_GlembatumumabVedotinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=cldx_Cdx014Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_YaleUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_MedimmuneLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=cldx_ObtainingSpecifiedRegulatoryAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=cldx_SpecifiedAnnualNetSalesThresholdsAreMetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |